Pharmaceuticals · Pharmaceuticals: Major · NSE: INDGN · data 2026-10-30

Indegene Limited

₹586.8-1.12% on 30 OctHealth: Strong 7.2/10

Feb 2026Low ₹423.5 · High ₹613.3+19.9%

In plain words

Price: 6.4% below its 52-week high of ₹627.

Delivery: 64.4% of traded shares were kept for delivery over the last 10 sessions, against 56.4% over the last 60.

A description of the data, not a recommendation.

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹586.8

Market cap

₹14,314 cr

P/E

34.5

P/B

4.2

ROE

13.9%

ROCE

15.9%

Debt / equity

0.05

Dividend yield

0.38%

1-year return

7.5%

52-week high

₹627

52-week low

₹414

Operating margin

12.4%

Growth

Revenue (last 12 months)	₹4,131 cr
Net profit (last 12 months)	₹411 cr
Sales growth, 3 years (yearly)	15.0%
Profit growth, 3 years (yearly)	14.7%

Smart-money activity

17/100 · Weak over the last ~60 sessions, data 2026-10-30

Delivery vs usual 4/30: Delivery 60.0% over the last 20 sessions vs 53.0% in the 40 before (1.13x); shares delivered per day 0.54x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
Mutual fund holding 5/15: 2 schemes hold it, about ₹142 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
Accumulation evidence 3/15: Verdict "None", sustained score 61/100.
Promoter pledges 5/5: No promoter pledge filings in 90 days.

A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.

Story so far

● Deal ● Dividend

8 Oct 26Deal Block deal: PI OPPORTUNITIES AIF V LLP bought ₹119.09 cr (net ₹0 cr) -4.4% next session
31 Jul 26Dividend Dividend ₹2.25 (ex-date) +5.9% next session
13 Jun 25Dividend Dividend ₹2 (ex-date) -1.0% next session

From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.

Common questions

Is Indegene Limited debt-free?

Its latest reported debt-to-equity ratio is 0.05, which is very low.

What is Indegene Limited's P/E ratio?

About 34.5, based on the last 12 months' earnings and a price of ₹586.8 (data 2026-10-30).

What is the 52-week high and low of Indegene Limited?

The 52-week high is ₹627 and the 52-week low is ₹414.

Mutual funds holding Indegene Limited

From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 2 schemes holding about ₹142 cr; funds that hold it outside their top holdings may not be listed.

Scheme	Fund house	% of fund	Value
SBI Innovative Opportunities Fund	SBI Mutual Fund	1.73%	₹89 cr
SBI Technology Opportunities Fund	SBI Mutual Fund	1.27%	₹53 cr

Similar companies

NATCO Pharma Limited (NATCOPHARM) · Jubilant Pharmova Limited (JUBLPHARMA) · Marksans Pharma Limited (MARKSANS) · Corona Remedies Limited (CORONA) · Anupam Rasayan India Ltd. (ANURAS)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open INDGN in NSE Scanner →